ESMO-MCBS v2.0: Advances, challenges, and perspectives in the assessment of clinical benefit in oncology

ESMO-MCBS v2.0: Advances, challenges, and perspectives in the assessment of clinical benefit in oncology Evaluating clinical benefits in oncology trials is critical for every facet of cancer care: from guiding clinical decisions, to informing regulatory approval, or shaping reimbursement. [1][2]][3] Unlike statistical significance, therapeutic benefit requires a metric that captures whether a new treatment delivers a clinically meaningful improvement in patient outcomes, a distinction that, in an era of increasingly complex treatment landscapes, carries the difference between real innovation and misguided marginal gains.Therefore, a rigorous and standardized framework for benefit assessment is essential to ensure that innovation translates into real-world values.The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a structured scoring system that translates trial results into a simple letter ranging from A (highest benefit) to C for curative therapies and from 5 (highest) to 1 for non-curative treatments.The scale assigns benefit scores based on predefined thresholds assessing overall survival (OS), disease-free survival, progression-free survival, quality of life (QoL), and treatment toxicity.As an example, Table 1 summarizes the ESMO-MCBS scores for therapies approved in advanced or unresectable hepatocellular carcinoma (HCC), based on phase III trials.In the first-line setting, atezolizumab-bevacizumab and durvalumabtremelimumab received the highest score of 5, supported by clinically meaningful gains in median OS (5.8 and 2.6 months), favorable hazard ratios (HR 0.66 and 0.78), and improvement in QoL.Durvalumab monotherapy was scored 4, based on non-inferiority (HR 0.86) and lower toxicity.Lenvatinib also met non-inferiority criteria (HR 0.92) but showed no QoL benefit and was classified as having no evaluable clinical benefit.In the second-line setting, cabozantinib (OS gain: 2.2 months; HR 0.76) and regorafenib (OS gain: 2.8 months; HR 0.63) provided modest survival benefits without QoL improvements.Notably, regorafenib was downgraded from score 4 to 3 in ESMO-MCBS v2.0 due to stricter scoring criteria (Table S1).Ramucirumab, restricted to patients with AFP > -400 ng/ml, showed minimal benefit (OS gain: 1.2 months; HR 0.71) and received the lowest score of 1.The newly released version 2.0 introduces several pivotal refinements that update the scale's precision, applicability, and